Fighting Cancer From Multiple Angles
Miguel A. Tam
Wednesday, May 17, 2017
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Outline
Cancer Treatment
Regulation of Cancer Cell Migration by RANKL
B16F10 Melanoma Cells Express RANK
RANKL Induces Cell Migration
RANKL Induces Actin Mobilization
RANKL Activates MAPK Signaling
RANKL Activates MAPK Signaling
NF-kB p50 binds to BIRC3
RANKL Signaling Regulation
OPG blocks RANKL-induced actin mobilization
OPG blocks RANKL-induced cell migration
OPG Controls Tumor Growth
Blocking monoclonal antibodies
Immune Checkpoints
In Vivo Treatment Experimental Design I
Activated phenotype of CD4 T Cells after PD-L1 treatment
Splenic Dendritic Cells Downregulate CD80 after PD-L1 treatment
Increased CD8a+ DCs in PD-L1 Treated dLN
Analytes screened
Increased Th Cytokines in Serum
Decreased Pro-Inflammatory Cytokines in Serum
Increased Chemokines in Serum
Cytokine and Chemokine Changes in Serum
Increased Specific CD8+ TIL at d24
PD-L1 injection controls tumor growth d24
Depleting monoclonal antibodies
Depleting Antibodies
In Vivo Treatment Experimental design II
Effective CD4 cell depletion
Activated phenotype of CD8 T cells after anti-CD4 treatment
No T Cell depletion with anti-PD-1 injection
Activated phenotype of CD4 T cells after anti-PD-1 treatment
Are the treatments able to revert the phenotype?
Conclusions
Acknowledgements
No transcript for this webinar
More Information
Contact us